---
title: "Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: References"
description: "Reference list for the formulary evidence report on Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria. 100 cited documents."
canonical: "https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/references"
published: "2026-09-21T21:42:40-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: References

<a id="references"></a>

## 5 References

1. [Balwani (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6656624/)
2. [Balwani and Desnick (2019)](https://www.ncbi.nlm.nih.gov/books/NBK121284/)
3. [Balwani et al. (2017a)](https://www.ncbi.nlm.nih.gov/books/NBK100826/)
4. [Balwani et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5710403/)
5. [Balwani et al. (2020)](https://ash.confex.com/ash/2020/webprogram/Paper142467.html)
6. [Balwani et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37043653/)
7. [Barman-Aksözen et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7437008/)
8. [Barman-Aksözen et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10094018/)
9. [Barman-Aksözen et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10580501/)
10. [Barman-Aksözen et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41885813/)
11. [Bell et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41902471/)
12. [Belongie et al. (2022)](https://www.jaad.org/article/S0190-9622(22)01702-9/fulltext)
13. [Biolcati et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25494545/)
14. [ClinicalTrials.gov NCT03520036](https://clinicaltrials.gov/study/NCT03520036)
15. [ClinicalTrials.gov NCT03520036 results](https://clinicaltrials.gov/study/NCT03520036?tab=results)
16. [ClinicalTrials.gov NCT04402489](https://clinicaltrials.gov/study/NCT04402489)
17. [ClinicalTrials.gov NCT04402489 results](https://clinicaltrials.gov/study/NCT04402489?tab=results)
18. [ClinicalTrials.gov NCT05005975](https://clinicaltrials.gov/study/NCT05005975)
19. [ClinicalTrials.gov NCT05020184](https://clinicaltrials.gov/study/NCT05020184)
20. [ClinicalTrials.gov NCT06144840](https://clinicaltrials.gov/study/NCT06144840)
21. [ClinicalTrials.gov NCT06910358](https://clinicaltrials.gov/study/NCT06910358)
22. [ClinicalTrials.gov NCT06994286](https://clinicaltrials.gov/study/NCT06994286)
23. [ClinicalTrials.gov NCT07820085](https://clinicaltrials.gov/study/NCT07820085)
24. [Clinuvel Pharmaceuticals (2017)](https://www.clinuvel.com/wp-content/uploads/2018/10/20170412GKV.pdf)
25. [Clinuvel Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/0001290877/000149315226013401/filename1.htm)
26. [Dechant et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12751534/)
27. [DerSarkissian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12653628/)
28. [Di Pierro et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8775248/)
29. [Dickey et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7796935/)
30. [Dickey et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9968824/)
31. [Disc Medicine bitopertin complete response letter announcement (2026)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526051504/iron-ex99_1.htm)
32. [Disc Medicine Form 10-K for fiscal year 2025 (2026)](https://www.sec.gov/Archives/edgar/data/1816736/000119312526073602/iron-20251231.htm)
33. [Elder et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23114748/)
34. [EU Clinical Trials Register (2021)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-001831-17/IT/)
35. [EU Clinical Trials Register (2023)](https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004226-16/results)
36. [European Medicines Agency (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2585)
37. [European Medicines Agency (2025)](https://www.ema.europa.eu/en/documents/product-information/scenesse-epar-product-information_en.pdf)
38. [Gemeinsamer Bundesausschuss (2021)](https://www.g-ba.de/downloads/39-1464-4906/2021-07-01_AM-RL-XII_Afamelanotid_D-641_EN.pdf)
39. [GondolaBio (2025)](https://gondolabio.com/portal-therapeutics-receives-u-s-fda-orphan-drug-and-fast-track-designations-for-port-77-for-the-treatment-of-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp/)
40. [GondolaBio (2026)](https://gondolabio.com/gondolabio-announces-positive-phase-2a-results-demonstrating-79-plasma-protoporphyrin-ix-reduction-and-disease-modifying-potential-of-port-77-for-erythropoietic-protoporphyria/)
41. [Graziadei et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8928159/)
42. [Holme et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16911284/)
43. [Horizonscan Geneesmiddelen (2026)](https://www.horizonscangeneesmiddelen.nl/geneesmiddelen/dersimelagon?lang=en)
44. [Jaramillo-Calle (2021)](https://pubmed.ncbi.nlm.nih.gov/32991848/)
45. [jRCT2080225355](https://jrct.mhlw.go.jp/latest-detail/jRCT2080225355)
46. [Kluijver et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11484138/)
47. [Kluijver et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12086420/)
48. [Lala et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6203604/)
49. [Langendonk et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/)
50. [LEO Pharma dersimelagon acquisition announcement (2026)](https://www.biospace.com/press-releases/leo-pharma-further-strengthens-late-stage-pipeline-with-the-acquisition-of-dersimelagon)
51. [LEO Pharma NDA acceptance and acquisition closing announcement (2026)](https://leo-pharma.com/media-center/news/leo-pharma-announces-fda-acceptance-of-dersimelagon-nda-with-priority-review-and-closes-acquisition-from-tanabe-pharma/)
52. [Levy et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10818013/)
53. [Levy et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11841850/)
54. [Madigan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10819203/)
55. [Mathias et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10660587/)
56. [McNamara (2026)](https://www.medscape.com/viewarticle/dersimelagon-meets-phase-3-endpoints-epp-and-xlp-2026a1000bcu)
57. [Minder et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11669082/)
58. [Mitsubishi Tanabe Pharma America (2024)](https://www.mt-pharma-america.com/media/press-releases/2024/first-patient-enrolled-in-mtpa-inspire-study-of-investigational-dersimelagon-for-epp-and-xlp)
59. [Mitsubishi Tanabe Pharma Development America (2019)](https://cdn.clinicaltrials.gov/large-docs/36/NCT03520036/Prot_000.pdf)
60. [Mitsubishi Tanabe Pharma Development America (2021)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/Prot_000.pdf)
61. [Mitsubishi Tanabe Pharma Development America (2022)](https://cdn.clinicaltrials.gov/large-docs/89/NCT04402489/SAP_001.pdf)
62. [Naik et al. (2019a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6850979/)
63. [Naik et al. (2019b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6660424/)
64. [Naik et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12009657/)
65. [Naik et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40781912/)
66. [Naik et al. (2025c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12486579/)
67. [NICE HST27 consideration of the evidence (2023)](https://www.nice.org.uk/guidance/hst27/chapter/4-Consideration-of-the-evidence)
68. [NICE HST27 recommendations (2023)](https://www.nice.org.uk/guidance/hst27/chapter/1-Recommendations)
69. [NICE HST27 the technology (2023)](https://www.nice.org.uk/guidance/hst27/chapter/3-The-technology)
70. [NIHR Innovation Observatory (2022)](https://www.io.nihr.ac.uk/wp-content/uploads/2022/06/26730-TSID_10392-Dersimelagon-for-Erythropoietic-Protoporphyria-V1.0-JUN2022-NON-CONF.pdf)
71. [NORD (2022)](https://rarediseases.org/rare-diseases/erythropoietic-protoporphyria/)
72. [Norwegian Medicines Agency (2018)](https://www.nyemetoder.no/48da6a/siteassets/documents/rapporter/afamelanotide-scenesse---hurtig-metodevurdering.pdf)
73. [Ogasawara et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10229459/)
74. [Ogasawara et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38746989/)
75. [Ogasawara et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11773107/)
76. [Ogasawara et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11783400/)
77. [Ogawa et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36840969/)
78. [Raef et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9857840/)
79. [Ross et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41527357/)
80. [Sato et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39641249/)
81. [Silver et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11883737/)
82. [Suzuki et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9060023/)
83. [Tanabe Pharma America (2024)](https://us.tanabe-pharma.com/media/press-releases/2024/first-patient-enrolled-in-mtpa-inspire-study-of-investigational-dersimelagon-for-epp-and-xlp)
84. [Tanabe Pharma America (2025)](https://us.tanabe-pharma.com/news-and-media/press-releases/2025/mitsubishi-tanabe-pharma-america-announces-completion-of-enrollment-for-its-phase-3-inspire-study-of-investigational-dersimelagon-in-patients-with-epp-and-xlp)
85. [Tanabe Pharma America (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-america-announces-positive-topline-results-for-dersimelagon-in-erythropoietic-protoporphyria-epp-and-x-linked-protoporphyria-xlp)
86. [Tanabe Pharma Corporation (2025)](https://www.tanabe-pharma.com/en/news/news20250701103099.html)
87. [Tanabe Pharma Corporation INSPIRE topline results announcement (2026)](https://www.tanabe-pharma.com/en/news/rel_260330/main/0/link/e_rel_260330.pdf)
88. [Tanabe Pharma Corporation LEO Pharma agreement announcement (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp)
89. [Tanabe Pharma Corporation NDA acceptance announcement (2026)](https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-announces-fda-acceptance-of-new-drug-application-for-dersimelagon-a-potential-first-in-class-oral-therapy-for-epp-and-xlp-and-the-completion-of-the-transfer-of-dersimelagon-business-ri)
90. [Thompson et al. (2016)](https://www.ispor.org/heor-resources/presentations-database/presentation/ispor-21st-annual-international-meeting/the-cost-effectiveness-of-afamelanotide-for-the-treatment-of-erythropoietic-protoporhyria)
91. [Tran et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12356314/)
92. [Tsuda et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116397/)
93. [US Food and Drug Administration (2019)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf)
94. [Ventura et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33021473/)
95. [Wensink et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7081144/)
96. [Wensink et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33941881/)
97. [Wensink et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34475006/)
98. [Wensink et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36579412/)
99. [Whatley et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20105171/)
100. [Yeung et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41390126/)

## Related pages
- [Dersimelagon (MT-7117): Erythropoietic protoporphyria or X-linked protoporphyria](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Terms and abbreviations](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/terms-and-abbreviations.md)
- [Dersimelagon (MT-7117): Erythropoietic protoporphyria or X-linked protoporphyria](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/executive-summary.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Product information and disease description](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/product-information-and-disease-description.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Clinical evidence](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/clinical-evidence.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Economic information and modeling report](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/economics) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/economics.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: prevalence by geography](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/prevalence) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/prevalence.md)
- [Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/cost-effectiveness-analyses.md)
